Investment Rating - The industry investment rating is "Positive" [1] Core Views - The report highlights that the pharmaceutical distribution sector is under pressure but is expected to see a recovery in profitability [3][6] - The report emphasizes the importance of new business models such as CSO and health device distribution, which are anticipated to support revenue growth [7] Summary by Sections Market Review - From January 1, 2025, to May 8, 2025, the pharmaceutical distribution index declined by 2.44%, underperforming the pharmaceutical and biotechnology index by 3.73 percentage points [4] - The market capitalization of pharmaceutical distribution in Q1 2025 was 1.5 billion, accounting for 0.05% of the total A-share fund holdings, showing a decrease from the previous quarter [4][20] Financial Analysis - Revenue growth for 2024 is projected at an average of 0.52%, a significant decline of 9.04 percentage points year-on-year. Major companies like China National Pharmaceutical and China Medicine are expected to experience negative growth [5][24] - In Q1 2025, the average revenue growth rate for key companies in pharmaceutical distribution was -0.11%, but this represents an improvement of 1.31 percentage points year-on-year [5][24] - The average net profit growth rate for key companies in Q1 2025 was 4.83%, an increase of 13.95 percentage points compared to the previous year [29][40] - The average gross profit margin for Q1 2025 was 8.33%, down 0.32 percentage points year-on-year, continuing a downward trend influenced by centralized procurement and drug pricing policies [32][40] Investment Recommendations - The report recommends focusing on leading companies in the pharmaceutical distribution sector, particularly those with strong capabilities in hospital payment recovery and innovative distribution channels. Key recommendations include Shanghai Pharmaceuticals, Jiuzhoutong, Baiyang Pharmaceuticals, and Zhongyao Holdings, with a watch on China National Pharmaceutical, Guoyao Holdings, and Liuyao Group [7][55]

| 证券代码：600713 | 证券简称：南京医药 | | --- | --- | | 债券代码：110098 | 债券简称：南药转债 | | 上海荣正企业咨询服务（集团）股份有限公司 | | | | 关于 | | 南京医药股份有限公司 | | | 首次授予及调整相关事项 | | | | 之 | | 独立财务顾问报告 | | | | 目 录 | | 一、释义 | | | 以下词语如无特殊说明，在本文中具有如下含义： | | | 南京医药、本公 | | | 司、公司、上市公 | 指 南京医药股份有限公司 | | 司 | | | 股权激励计划、本 | | | 指 | 南京医药股份有限公司 2025 年限制性股票激励计划 | | 激励计划 | | | | 公司根据本激励计划规定的条件和价格，授予激励对象一 | | | 定数量的公司股票，该等股票设置一定期限的限售期，在 | | 限制性股票 指 | | | | 达到本激励计划规定的解除限售条件后，方可解除限售流 | | 通 | | | | 按照本激励计划规定，获得限制性股票的公司董事、高级 | | 激励对象 指 | | | | 管理人员、公司及控股子公司核心管理/骨干 ...

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected relative increase in stock price of over 20% compared to the benchmark index within the next six months [10][14]. Core Insights - The company has shown stable growth in its core pharmaceutical distribution business, achieving a revenue of 151.81 billion yuan in 2024, reflecting a year-on-year increase of 1.11%. The net profit attributable to shareholders reached 2.507 billion yuan, up by 15.33% [3][6]. - The successful issuance of public REITs has significantly contributed to the company's net profit, adding 576 million yuan in 2024 and 438 million yuan in Q1 2025 [4][9]. - The company is pioneering a dual listing platform in the pharmaceutical industry, combining equity and asset listings, which enhances its asset liquidity and sets a benchmark for the industry [7][9]. Financial Performance Summary - For 2024, the company reported an operating income of 151.81 billion yuan, with a net profit of 2.507 billion yuan. The operating cash flow was 3.083 billion yuan, although it saw a decline of 35.07% year-on-year [3][5]. - In Q1 2025, the company achieved an operating income of 42.016 billion yuan, a 3.82% increase, and a net profit of 970 million yuan, which is an impressive growth of 80.38% compared to the previous year [4][10]. - The company’s gross margin for 2024 was 7.80%, with a net profit margin of 1.65%. In Q1 2025, the gross margin slightly decreased to 7.33%, while the net profit margin improved to 2.31% [4][5]. Growth Projections - The company is expected to continue its growth trajectory, with projected revenues of 162.65 billion yuan, 174.30 billion yuan, and 186.62 billion yuan for 2025, 2026, and 2027 respectively. The net profit is forecasted to reach 3.010 billion yuan in 2025, growing to 3.458 billion yuan by 2027 [10][12].

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected relative increase in stock price of over 20% compared to the benchmark index within the next six months [10][14]. Core Insights - The company has shown stable growth in its core pharmaceutical distribution business, achieving a revenue of 151.81 billion yuan in 2024, reflecting a year-on-year increase of 1.11%. The net profit attributable to shareholders reached 2.507 billion yuan, up by 15.33% [3][6]. - The successful issuance of public REITs has significantly contributed to the company's net profit, adding 576 million yuan in 2024 and 438 million yuan in Q1 2025 [4][9]. - The company is pioneering a dual listing platform in the pharmaceutical industry, combining equity and asset listings, which enhances its asset liquidity and sets a benchmark for the industry [7][9]. Financial Performance Summary - For 2024, the company reported an operating income of 151.81 billion yuan, with a net profit of 2.507 billion yuan. The operating cash flow was 3.083 billion yuan, showing a decline of 35% year-on-year due to increased payments to core suppliers [3][5][10]. - The first quarter of 2025 saw an operating income of 42.016 billion yuan, a 3.82% increase, and a net profit of 970 million yuan, marking an 80.38% rise compared to the previous year [4][10]. - The company’s gross margin for 2024 was 7.80%, with a net profit margin of 1.65%. In Q1 2025, the gross margin slightly decreased to 7.33%, while the net profit margin improved to 2.31% [4][5]. Growth Projections - The company is expected to achieve revenues of 162.65 billion yuan, 174.30 billion yuan, and 186.62 billion yuan for the years 2025, 2026, and 2027, respectively. The net profit attributable to shareholders is projected to be 3.010 billion yuan, 3.212 billion yuan, and 3.458 billion yuan for the same years [10][12]. - The report anticipates a steady growth rate of approximately 7% for the upcoming years, with a corresponding increase in earnings per share [10][12].

Core Viewpoint - The company showcased its stable growth and strategic initiatives during the 2024 annual performance briefing, highlighting significant financial achievements and advancements in digital transformation and ESG practices [1][2][3][4] Financial Performance - In 2024, the company reported revenue of 151.81 billion yuan and a net profit attributable to shareholders of 2.507 billion yuan, with a year-on-year revenue growth of 2.58% and a net profit growth of 39.88% after adjusting for seasonal factors [1] - For Q1 2025, the company achieved revenue of 42.016 billion yuan, a 3.82% increase year-on-year, and a net profit of approximately 970 million yuan, reflecting an 80.38% growth compared to the same period last year [1] Shareholder Returns - The company plans to distribute a cash dividend of 2.00 yuan per 10 shares, totaling 999.7 million yuan, which, combined with the stock buyback of 268 million yuan, amounts to 1.265 billion yuan, representing 50.47% of the annual net profit [2] Asset Securitization - The company successfully established an asset securitization platform, with its public REITs for pharmaceutical logistics warehousing listed on the Shanghai Stock Exchange, marking a significant milestone as the first public REITs in the domestic pharmaceutical sector [2] Digital Transformation - The company is actively embracing AI technology through both in-house development and external collaborations, partnering with leading tech firms like Alibaba Cloud and Tencent Cloud to enhance its digital capabilities across various applications [2] ESG Practices - Over the past three years, the company has developed a robust ESG management system, achieving an A rating in mainstream ESG assessments and ranking first in the pharmaceutical distribution industry for 2024 [3] Strategic Initiatives - The company highlighted its achievements in new products, new retail, and new medical services during the performance briefing, emphasizing its commitment to strategic transformation and future growth [4]

Group 1 - The core viewpoint of the news is that Jiuzhoutong has successfully established itself as a leader in the pharmaceutical logistics sector by launching the first public REITs and Pre-REITs fund in China, enhancing its asset management capabilities and market value [1][2] - Jiuzhoutong's 2024 revenue reached 151.81 billion yuan, with a net profit attributable to shareholders of 2.507 billion yuan, reflecting a year-on-year revenue growth of 2.58% and a net profit growth of 39.88% after adjusting for seasonal factors [2] - In Q1 2025, Jiuzhoutong reported a revenue of 42.016 billion yuan, a 3.82% increase year-on-year, and a net profit of approximately 970 million yuan, marking an 80.38% increase compared to the same period last year [2] Group 2 - The issuance of public REITs is a significant part of Jiuzhoutong's strategic transformation, aimed at revitalizing its pharmaceutical logistics assets and facilitating rapid business growth [1] - Jiuzhoutong has become the first company in the pharmaceutical industry to establish a dual listing platform of "equity + assets," setting a benchmark for asset management in the pharmaceutical distribution sector [1]

Core Insights - The company is focusing on digital transformation and AI integration to enhance its business operations and management efficiency [1][2] Group 1: Digital Transformation and AI Strategy - The company has accelerated its digital transformation strategy, investing significantly in AI technology and innovation, with a research and development expenditure of 346 million yuan in 2024, representing a 24.32% increase year-on-year [1] - The company has implemented 47 digital transformation projects, with 45 successfully launched, applying digital technology across various business scenarios, including operations and logistics [1] - The company collaborates with leading tech firms like Alibaba Cloud and Tencent Cloud to develop AI applications tailored to different business needs, enhancing its smart management capabilities [2] Group 2: Financial Performance - In 2024, the company reported a revenue of 151.81 billion yuan and a net profit attributable to shareholders of 2.507 billion yuan, with a year-on-year revenue growth of 2.58% and a net profit growth of 39.88% after adjusting for seasonal factors [2] - For the first quarter of 2025, the company achieved a revenue of 42.016 billion yuan, a 3.82% increase compared to the same period last year, and a net profit of approximately 970 million yuan, reflecting an 80.38% year-on-year growth [2]

Performance - In 2024, the company achieved total operating revenue of 151.81 billion, a year-on-year increase of 1.11%; net profit attributable to shareholders was 2.51 billion, up 15.33%; and net profit excluding non-recurring items was 1.81 billion, down 7.47% [1] - In Q1 2025, total operating revenue reached 42.02 billion, a year-on-year increase of 3.82%; net profit attributable to shareholders was 970 million, a significant increase of 80.38%; and net profit excluding non-recurring items was 507 million, down 2.76% [1] Growth Potential - The company successfully launched its REITs, marking a new chapter in light asset operations, with the public offering of pharmaceutical warehousing logistics REITs raising 1.16 billion on February 27, 2025 [2] - The CSO business continued to grow, achieving sales revenue of 19.27 billion, with pharmaceutical CSO revenue at 10.77 billion, a year-on-year increase of 19.59% after adjusting for high base effects [2] New Retail and New Medical - The "Good Pharmacist" franchise rapidly expanded, reaching 29,331 stores by the end of March 2025, with sales to franchise pharmacies amounting to 5.39 billion, a year-on-year increase of 54.94% [3] - The "Nine Medical Clinics" membership stores reached 1,377 by the end of March 2025, utilizing AI-assisted diagnostic platforms to empower grassroots medical institutions [3] Profitability - The overall gross margin for 2024 was 7.80%, a decrease of 0.27 percentage points, while Q1 gross margin was 7.33%, an increase of 0.13 percentage points [4] - The net profit margin attributable to shareholders for 2024 was 1.65%, an increase of approximately 0.21 percentage points, with Q1 2025 net profit margin at 2.31%, a significant increase of 0.98 percentage points [4] Operating Quality - The net cash flow from operating activities in 2024 was 3.08 billion, a year-on-year decrease of 35.07%, primarily due to increased procurement payments from strategic cooperation with core suppliers [5] - By Q1 2025, the company's operating cash flow remained stable year-on-year, with slight increases in accounts receivable turnover days and inventory turnover days [5] Profit Forecast and Valuation - Revenue projections for 2025-2027 are 163.29 billion, 176.46 billion, and 190.08 billion, with corresponding growth rates of 7.56%, 8.06%, and 7.72% [6] - Expected net profits attributable to shareholders for the same period are 2.84 billion, 3.18 billion, and 3.54 billion, with year-on-year growth rates of 13.13%, 12.08%, and 11.21% [6]

Core Viewpoint - The strategic transformation of the company, driven by the "Three New and Two Digital" strategy, has led to steady growth in performance, with significant increases in revenue and profit in 2024 and Q1 2025 [2][3][5]. Financial Performance - In 2024, the company achieved a total revenue of 151.81 billion yuan, a year-on-year increase of 1.11%, and a net profit attributable to shareholders of 2.507 billion yuan, up 15.33% [3][5]. - The net cash flow from operating activities turned positive at 3.083 billion yuan [3]. - For Q1 2025, the company reported revenue of 42.016 billion yuan, a growth of 3.82%, and a net profit of approximately 970 million yuan, an increase of 80.38% [4][5]. Business Segments - The core pharmaceutical distribution business showed stable growth, while emerging sectors like industrial self-production, OEM, traditional Chinese medicine, and digital logistics grew rapidly, each with a growth rate around 20% [3][4]. - The industrial self-production and OEM segment generated sales of 5.92 billion yuan, up 26.92%, with a gross margin of 42.48% [3]. - The traditional Chinese medicine segment achieved sales of 4.962 billion yuan, a growth of 18.14%, supported by a blockchain-based quality traceability platform [4]. Strategic Initiatives - The company is focusing on new product strategies, with sales from the pharmaceutical agency brand promotion business reaching 19.267 billion yuan, introducing 2,247 drug and device specifications [5][6]. - The new retail strategy has established over 29,000 franchise pharmacies, with B2C e-commerce sales reaching 980 million yuan and over 35 million end-users [5][6]. - The new medical strategy includes the development of an AI-assisted diagnostic platform in collaboration with Tencent Cloud, enhancing service efficiency for clinics and grassroots medical institutions [6]. Digital Transformation - The company invested 346 million yuan in digital and intelligent technology innovation, with 47 digital transformation projects implemented, 45 of which have been successfully launched [6]. - The logistics segment achieved revenue of 1.064 billion yuan, a growth of 25.32%, with a gross profit of 236 million yuan, up 17.08% [4]. Real Estate Investment Trusts (REITs) - The company completed the issuance of public REITs for its pharmaceutical warehousing and logistics, raising 1.158 billion yuan, marking a significant step towards asset-light transformation [7]. - The public REITs issuance saw a subscription multiple of 1,192 times, setting a historical record for public REITs [7].

证券代码：000950 证券简称：重药控股 重药控股股份有限公司投资者关系活动记录表 编号：2025-004 | | □特定对象调研 □分析师会议 | | --- | --- | | 投资者关系活动类 | □媒体采访 业绩说明会 | | 别 | □新闻发布会 □路演活动 | | | □现场参观 | | | □其他（请文字说明其他活动内容） | | | 线上参与公司 年度业绩说明会的投资者 2024 上市公司接待人员： | | | 董事长 袁泉 | | 活动参与人员 | 独立董事 刘胜强 | | | 财务总监、董事会秘书 邱天 | | | 证券事务代表 赵婧 | | 时间 | 年 月 日下午 2025 5 6 15:00-16:00 | | 地点 | 价值在线（www.ir-online.cn） | | 形式 | 网络互动方式 | | | 1、重药控股如何促进提高国有资产的保值增值，切实回报 | | | 投资者。 重药控股上市有 年多了，股价长时间低于净资产值， 6 | | | 至今股价也低于 2017 年重药上市时的配售发行价（5.93 元/股）， | | | 令战略投资者和普通投资者在 年多时间里，长期处 ...